214450.KQ 21

214450.KQ PharmaResearch Co., Ltd.

Healthcare · Biotechnology

4 · Feble Momentum 0.0 · Feble Segur ratxa de 6a

247500.00

-0.60%

Sobre l'empresa

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

1.49% prevista
—
1.49% 3700.00 KRW
3700.00
2.6T
—
—
330952.50

Rang 52 setmanes

247500
mín 0.00 màx 561000
Rendibilitat Creixement Momentum Seguretat Valor Salut

Anàlisi a fons del dividend

PharmaResearch Co., Ltd. (214450.KQ) is an equity. The company currently offers a dividend yield of 1.49%. Information regarding its dividend safety status, momentum score, and value score is not provided in the data. The 5-year average, low, and high yield band data are also missing, preventing a comparison of the current yield to its historical range.

Historial de dividends

The dividend history for PharmaResearch Co., Ltd. (214450.KQ) shows a current annual dividend of 3,700 KRW. The data does not provide a streak of consecutive dividend increases. Similarly, the 3-year and 5-year dividend Compound Annual Growth Rates (CAGR) are missing from the provided information. The year-by-year dividend history is also not available in the dataset. Therefore, a detailed analysis of past dividend growth and consistency cannot be performed based on the provided figures.

Seguretat del dividend

Assessing the safety of PharmaResearch Co., Ltd.'s dividend of 3,700 KRW is limited by the available data. The payout ratio, which indicates what percentage of earnings are distributed as dividends, is missing.

Quantic · Gratis

Llegeix la resta de la seguretat del dividend

A més, els riscos clau i què vigilar tot seguit. Gratis, sense targeta.

Generat per IA a partir de les dades de dividends de Quantic · Actualitzat el 11 Nov 2026 · Només informatiu — no és assessorament financer.

Es mostra en anglès — la traducció està en camí.

Historial de preus

680000 368100 56200 2021 2022 2023 2024 2025 2026 2020-11 · 57200 2020-12 · 61600 2021-01 · 56200 2021-02 · 66300 2021-03 · 70000 2021-04 · 84200 2021-05 · 90000 2021-06 · 88800 2021-07 · 96900 2021-08 · 84700 2021-09 · 92000 2021-10 · 77200 2021-11 · 82000 2021-12 · 75400 2022-01 · 87100 2022-02 · 91800 2022-03 · 93000 2022-04 · 82700 2022-05 · 67400 2022-06 · 72600 2022-07 · 67500 2022-08 · 56600 2022-09 · 61500 2022-10 · 67000 2022-11 · 69900 2022-12 · 77200 2023-01 · 74400 2023-02 · 70200 2023-03 · 101000 2023-04 · 114700 2023-05 · 143700 2023-06 · 133200 2023-07 · 144900 2023-08 · 126500 2023-09 · 116400 2023-10 · 108400 2023-11 · 109500 2023-12 · 105300 2024-01 · 93900 2024-02 · 100900 2024-03 · 127600 2024-04 · 146100 2024-05 · 148800 2024-06 · 134100 2024-07 · 174500 2024-08 · 192700 2024-09 · 225500 2024-10 · 198000 2024-11 · 262500 2024-12 · 241500 2025-01 · 291000 2025-02 · 332000 2025-03 · 376500 2025-04 · 451000 2025-05 · 493500 2025-06 · 557000 2025-07 · 680000 2025-08 · 601000 2025-09 · 541000 2025-10 · 470000 2025-11 · 403000 2025-12 · 473500 2026-01 · 349500 2026-02 · 299000 2026-03 · 313500 2026-04 · 295000 2026-05 · 363000 2026-06 · 338500 2026-07 · 426000 2026-08 · 310500 2026-09 · 212000 2026-10 · 249000 2026-11 · 247500
Preu

Perfil de dividends

Freqüència
Anual
Creixement (TTM)
+236.4%
CAGR 3a
+77.6%
+49.2%
6 anys

(5 anys)

Ara 1.5%
0.7% mitj. 0.8% 0.9%

Gen
Feb
Mar
Abr
Mai
Jun
Jul
Ago
Set
Oct
Nov
Des

Els diners solen arribar després, de vegades un mes o més tard.

Historial de dividends

CAGR 3a +77.6% CAGR 5a +49.2% ratxa de 6a
15 16 17 18 19 20 21 22 23 24 25

Dividend per acció per any

Quantic · Gratis

Desbloqueja valoració i estratègia

Dos valors raonables per DDM, marge de seguretat, rànquing de valor del sector, Teoria del Rendiment per Dividend, temps de duplicació i caiguda màxima.

Deute i palanquejament

27.9%
7.78
6.61
Deute vs efectiu
Deute Efectiu
Deute total
220.3B KRW
Efectiu total
595.6B KRW
252.6B KRW

Últimes xifres del balanç publicades.

Apareix en aquestes llistes

214450.KQ compleix els criteris d'aquests rànquings de dividends.

Només informatiu — no és assessorament financer.

Quantic · Gratis

Segueix 214450.KQ i tota la teva cartera

Rendiment real, seguretat del dividend, ingressos nets d'impostos i el teu camí cap a la llibertat — gratis, sense connexió amb el bróker.

€0

Necessites més? El Pro afegeix carteres, seguiment d'ingressos per opcions i més IA. Descobreix el Pro →